TideMedix review

TideMedix needs written clarification before a purchase decision: its public price surfaces disagree, the treating practice and dispensing assignment remain unestablished, and an injection offer sits beside a policy saying refrigerated products are not shipped. These gaps make the continuing cost and fulfillment conditions too uncertain to recommend without clarification.

TideMedix presents an online assessment followed by provider review and prescription fulfillment when clinically appropriate. Its terms refer to TideMedix, owners, affiliates and third parties, without establishing the actual professional practice responsible for an individual prescription. A HIPAA notice describes TideMedix pharmacists and pharmacy employees; that pharmacy-oriented language does not identify the prescribing practice. The returns page gives a TideMedix/Manifest Pharmacy address in Greer, South Carolina. A returns address is a useful lead, but it does not prove that Manifest will dispense every order. Ask for both the treating legal practice and the actual pharmacy before paying. The site also claims LegitScript certification and licensed-provider review. We report those as company claims, without treating them as independent verification of credentials, product approval or the care received by a particular patient. This assessment is based on public disclosures, rather than firsthand use or medical endorsement.

The landing page says the assessment can begin without payment and that eligible applicants see options and pricing before checkout. A clinician reviews the submitted history before issuing any prescription. Terms make clear that care and a prescription are not guaranteed. The process should therefore be understood as an application for clinical assessment, not a reservation of medication. Public pages did not establish a complete service-state list. The expanded go-subdomain FAQ says most United States states are supported and that checkout confirms eligibility; the main-domain FAQ instead describes variation with telehealth rules, provider availability and pharmacy requirements. Neither supports an all-fifty-state claim. Confirm the state in which you will physically receive care as well as the shipping destination. The reviewed material also did not establish a universal numerical eligibility threshold, the assigned clinician or the exact follow-up schedule. Ask who handles side-effect questions, refill decisions and records requests. If another pharmacy is preferred, the terms say to email support before completing an order. That choice may require a different fulfillment arrangement, so confirm the effect on the quoted bill rather than assuming the advertised package transfers unchanged.

Three official price surfaces need to be kept separate. The go-subdomain landing page advertises weekly semaglutide injections from $99 for the first month, then $197 monthly, and tirzepatide injections from $199 initially, then $397 monthly if prescribed. The actual expanded FAQ on that same subdomain instead lists compounded semaglutide from $149 monthly and compounded tirzepatide from $249 monthly, with reduced monthly rates for multi-month plans. The main-domain FAQ gives no numeric quote and says prices vary by product path, plan length and fulfillment option, with current details shown during assessment and checkout. We cannot tell from these pages which schedule governs a proposed order, what dose and supply it covers, or what commitment the discounted terms require. The conflicting schedules do not establish a dependable continuing bill. Obtain the full initial charge, recurring authorization, quantity and dose limits in writing. Refund language also differs. The go FAQ promises a full refund after physician denial, while describing other requests as support cases and shipped-medication refunds as case-by-case. The main FAQ gives a general plan-and-order-dependent answer. Separately, the returns policy says prescription sales are final once payment has been charged and the parcel handed to the carrier, and that dispensed prescription medication cannot be returned. It allows account cancellation before products ship, but does not establish a precise advance-renewal deadline. These are materially different situations: clinical denial, stopping a future subscription and seeking money back after fulfillment. Ask which policy controls your plan and save the answer. A cancel-anytime statement does not by itself promise repayment of an already processed prescription.

The go landing page explicitly describes weekly injections, and its expanded FAQ calls the semaglutide and tirzepatide plans compounded. The main-domain FAQ mentions oral-pill and injection-shot paths for education and assessment routing. That does not establish an exact oral formulation, a currently dispensable oral GLP-1 product or equivalence to an approved tablet. The main site discloses that compounded products are not FDA-approved. Obtain the actual ingredient, concentration, supply, prescribed instructions and dispensing label before making product comparisons. Shipping deserves particular attention. The go FAQ advertises two-day shipping after approval and processing; the main FAQ gives a variable timeline through the patient-order process. Most significantly, the returns policy says TideMedix does not currently ship refrigerated products and suggests transit delays will not affect them. That statement cannot be used to infer the stability of the advertised injections. It also cannot establish that every injection requires the same handling. Ask the assigned pharmacy for the preparation-specific shipping conditions, storage instructions, acceptable transit exposure and procedure for a delayed or damaged delivery before ordering. The returns policy says a package lost in transit can be investigated and reshipped, and directs damaged-shipment concerns to support. A general replacement promise does not resolve a temperature excursion or establish usability. Those questions belong with the dispensing pharmacist and prescriber, not a generic fulfillment banner.